Ji-chen Ho
Taoyuan, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.
Journal: The Journal of dermatology
Published: February 08, 2025
Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial.
Journal: The British journal of dermatology
Published: May 31, 2024
TNF-α Activating Osteoclasts in Patients with Psoriatic Arthritis Enhances the Recruitment of Osteoclast Precursors: A Plausible Role of WNT5A-MCP-1 in Osteoclast Engagement in Psoriatic Arthritis.
Journal: International journal of molecular sciences
Published: November 14, 2021
Upregulation of miR-941 in Circulating CD14+ Monocytes Enhances Osteoclast Activation via WNT16 Inhibition in Patients with Psoriatic Arthritis.
Journal: International journal of molecular sciences
Published: May 11, 2020
Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: February 25, 2020
Targeting steroid receptor RNA activator (SRA), a long non-coding RNA, enhances melanogenesis through activation of TRP1 and inhibition of p38 phosphorylation.
Journal: PloS one
Published: December 27, 2019
Steroid Receptor RNA Activator, a Long Noncoding RNA, Activates p38, Facilitates Epithelial-Mesenchymal Transformation, and Mediates Experimental Melanoma Metastasis.
Journal: The Journal of investigative dermatology
Published: February 10, 2019
MiR-146a-5p Expression in Peripheral CD14⁺ Monocytes from Patients with Psoriatic Arthritis Induces Osteoclast Activation, Bone Resorption, and Correlates with Clinical Response.
Journal: Journal of clinical medicine
Published: November 14, 2018
Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation.
Journal: Journal of dermatological science
Published: November 27, 2017
Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions.
Journal: The Journal of clinical investigation
Published: February 10, 2017
Treatment of Pigmented Basal Cell Carcinoma with 3 mm Surgical Margin in Asians.
Journal: BioMed research international
Published: June 29, 2016
No Significant Reduction of Circulating Endothelial-Derived and Platelet-Derived Microparticles in Patients with Psoriasis Successfully Treated with Anti-IL12/23.
Journal: BioMed research international
Published: January 21, 2016
Last Updated: 09/26/2026